Evidence map›Paper›PMID 25825450›Full record

ArticleJournal of immunology (Baltimore, Md. : 1950)2015

Ability to develop broadly neutralizing HIV-1 antibodies is not restricted by the germline Ig gene repertoire.

Cathrine Scheepers, Ram K Shrestha, Bronwen E Lambson, Katherine J L Jackson, Imogen A Wright, Dshanta Naicker, Mark Goosen, Leigh Berrie, Arshad Ismail, Nigel Garrett and 5 more

Open access · bronzeAbstract read
In one paragraph

Article in Journal of immunology (Baltimore, Md. : 1950), 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 48 papers.

0numbers the graph read from it
0cells of the map it votes in
48citing papers in PubMed
5.2field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

48 citing papers in PubMed, 78 citations in OpenAlex.

  1. Trial
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Review
  16. Article
  17. Article
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 7 institutions in 3 countries.

Cathrine ScheepersCentre for HIV and Sexually Transmitted Infections, National Institute for Communicable Diseases of the National Health Laboratory Service, Johannesburg 2131, South Africa; Division of Virology and Communicable Disease Surveillance, School of Pathology, University of the Witwatersrand, Johannesburg 2050, South Africa;
Ram K ShresthaSouth African National Bioinformatics Institute, South African Medical Research Council Bioinformatics Unit, University of the Western Cape, Bellville 7535, South Africa;
Bronwen E LambsonCentre for HIV and Sexually Transmitted Infections, National Institute for Communicable Diseases of the National Health Laboratory Service, Johannesburg 2131, South Africa; Division of Virology and Communicable Disease Surveillance, School of Pathology, University of the Witwatersrand, Johannesburg 2050, South Africa;
Katherine J L JacksonSchool of Biotechnology and Biomolecular Sciences, University of New South Wales, Sydney, New South Wales 2052, Australia; Department of Pathology, School of Medicine, Stanford University, Stanford, CA 94305;
Imogen A WrightSouth African National Bioinformatics Institute, South African Medical Research Council Bioinformatics Unit, University of the Western Cape, Bellville 7535, South Africa;
Dshanta NaickerCentre for HIV and Sexually Transmitted Infections, National Institute for Communicable Diseases of the National Health Laboratory Service, Johannesburg 2131, South Africa;
Mark GoosenCentre for HIV and Sexually Transmitted Infections, National Institute for Communicable Diseases of the National Health Laboratory Service, Johannesburg 2131, South Africa;
Leigh BerrieCentre for HIV and Sexually Transmitted Infections, National Institute for Communicable Diseases of the National Health Laboratory Service, Johannesburg 2131, South Africa;
Arshad IsmailCentre for HIV and Sexually Transmitted Infections, National Institute for Communicable Diseases of the National Health Laboratory Service, Johannesburg 2131, South Africa;
Nigel GarrettCentre for the AIDS Programme of Research in South Africa, KwaZulu-Natal 4013, South Africa; Department of Infectious Diseases, Nelson R. Mandela School of Medicine, University of KwaZulu-Natal, 4041 Durban, South Africa; and.
Quarraisha Abdool KarimCentre for the AIDS Programme of Research in South Africa, KwaZulu-Natal 4013, South Africa; Department of Epidemiology, Columbia University, New York, NY 10032.
Salim S Abdool KarimCentre for the AIDS Programme of Research in South Africa, KwaZulu-Natal 4013, South Africa; Department of Epidemiology, Columbia University, New York, NY 10032.
Penny L MooreCentre for HIV and Sexually Transmitted Infections, National Institute for Communicable Diseases of the National Health Laboratory Service, Johannesburg 2131, South Africa; Division of Virology and Communicable Disease Surveillance, School of Pathology, University of the Witwatersrand, Johannesburg 2050, South Africa; Centre for the AIDS Programme of Research in South Africa, KwaZulu-Natal 4013, South Africa;
Simon A TraversSouth African National Bioinformatics Institute, South African Medical Research Council Bioinformatics Unit, University of the Western Cape, Bellville 7535, South Africa;
Lynn MorrisCentre for HIV and Sexually Transmitted Infections, National Institute for Communicable Diseases of the National Health Laboratory Service, Johannesburg 2131, South Africa; Division of Virology and Communicable Disease Surveillance, School of Pathology, University of the Witwatersrand, Johannesburg 2050, South Africa; Centre for the AIDS Programme of Research in South Africa, KwaZulu-Natal 4013, South Africa; lynnm@nicd.ac.za.
National Health Laboratory Service · ZACentre for the AIDS Programme of Research in South Africa · ZASouth African Medical Research Council · ZAUniversity of the Witwatersrand · ZAColumbia University · USUniversity of the Western Cape · ZAUNSW Sydney · AU

Funding

The Viral Set Point in HIV-1 Subtype C InfectionU19AI051794 · NIAID · UNIVERSITY OF KWAZULU-NATAL · PI ABDOOL KARIM, SALIM S · 2002 to 2007
$22.5M
TUBERCULOSIS SUPPLEMENTD43TW000231 · FIC · COLUMBIA UNIV NEW YORK MORNINGSIDE · PI ABDOOL KARIM, QUARRAISHA · 1993 to 2014
$13.1M
FIC NIH HHS 5 D43TW000231FIC NIH HHS D43 TW000231NIAID NIH HHS AI51794NIAID NIH HHS U19 AI051794Wellcome TrustWellcome Trust 089933/Z/09/Z
6 · The paper itself

Abstract

The human Ig repertoire is vast, producing billions of unique Abs from a limited number of germline Ig genes. The IgH V region (IGHV) is central to Ag binding and consists of 48 functional genes. In this study, we analyzed whether HIV-1-infected individuals who develop broadly neutralizing Abs show a distinctive germline IGHV profile. Using both 454 and Illumina technologies, we sequenced the IGHV repertoire of 28 HIV-infected South African women from the Centre for the AIDS Programme of Research in South Africa (CAPRISA) 002 and 004 cohorts, 13 of whom developed broadly neutralizing Abs. Of the 259 IGHV alleles identified in this study, approximately half were not found in the International Immunogenetics Database (IMGT). This included 85 entirely novel alleles and 38 alleles that matched rearranged sequences in non-IMGT databases. Analysis of the rearranged H chain V region genes of mAbs isolated from seven of these women, as well as previously isolated broadly neutralizing Abs from other donors, provided evidence that at least eight novel or non-IMGT alleles contributed to functional Abs. Importantly, we found that, despite a wide range in the number of IGHV alleles in each individual, including alleles used by known broadly neutralizing Abs, there were no significant differences in germline IGHV repertoires between individuals who do and do not develop broadly neutralizing Abs. This study reports novel IGHV repertoires and highlights the importance of a fully comprehensive Ig database for germline gene usage prediction. Furthermore, these data suggest a lack of genetic bias in broadly neutralizing Ab development in HIV-1 infection, with positive implications for HIV vaccine design.

Indexed as

Antibodies, NeutralizingGenes, ImmunoglobulinAdultAllelesBlack PeopleFemaleGerm CellsHIV-1HIV AntibodiesHIV InfectionsHumansImmunoglobulin Heavy ChainsImmunoglobulin Variable RegionPhylogenyYoung AdultAntibodies, NeutralizingHIV AntibodiesImmunoglobulin Heavy ChainsImmunoglobulin Variable Region

Identifiers

PMID25825450
PMCPMC4513073
OpenAlexW1948278385

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.